VectorY Therapeutics raised EUR 74.5 million to advance its pipeline for amyotrophic lateral sclerosis and other neurodegenerative diseases. The Amsterdam biotechnology company develops vectorised antibody treatments intended to deliver therapeutic proteins in the nervous system. Invest-NL committed EUR 7 million as part of the financing. The announcement did not assign a conventional Series stage or identify one lead investor, so both are recorded conservatively. The capital will support research, manufacturing and clinical development. The financing and Dutch base were confirmed through the company announcement and Invest-NL.
VectorY Therapeutics raises EUR 74.5m for ALS gene therapies
New financing supports development of vectorised antibody treatments.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


